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S U M M A R Y
Objectives: To retrospectively investigate the incidence of and factors associated with skin rashes and
hepatotoxicity in HIV-infected patients who initiated combination antiretroviral therapy (cART)
containing nevirapine plus two nucleos(t)ide reverse-transcriptase inhibitors.
Methods: The medical records of HIV-infected adult patients who started nevirapine-containing cART
and continued follow-up for 4 weeks were reviewed at two hospitals in Taiwan between 2000 and
2012. Clinical data obtained at baseline and during follow-up were collected and analyzed.
Results: Of the 338 patients included in the analysis, 13.0% tested positive for hepatitis B virus surface
antigen and 7.9% tested positive for anti-hepatitis C virus antibody. The incidence of rashes was 21.6%
and of hepatotoxicity was 25.5%. On multiple logistic regression analysis, a two-fold or greater increase
from the upper limit of normal levels of aminotransferases at baseline was associated with rashes
(adjusted odds ratio (aOR) 3.74, 95% conﬁdence interval (CI) 1.56–8.96); higher CD4 counts (aOR for per
50 cells/ml increase 1.51, 95% CI 1.12–2.03) and the concurrent use of trimethoprim/sulfamethoxazole
(aOR 14.01, 95% CI 1.98–98.95) were associated with hepatotoxicity.
Conclusions: Abnormal liver function at baseline was signiﬁcantly associated with skin rashes, while a
higher CD4 count and the concurrent use of trimethoprim/sulfamethoxazole were associated with
hepatotoxicity after the initiation of nevirapine-containing cART in HIV-infected Taiwanese patients.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Nevirapine (NVP) remains a potent non-nucleoside reverse-
transcriptase inhibitor (nNRTI) when used in combination with
two nucleoside reverse-transcriptase inhibitor (NRTIs), as per the* Corresponding author. Tel.: +886 2 23123456 ext. 67552; fax: +886 2 23707772.
E-mail address: hcc0401@ntu.edu.tw (C.-C. Hung).
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).recommended treatment regimen of the European AIDS Clinical
Society before 2012 for antiretroviral-naı¨ve HIV-1-infected
patients in areas where the prevalence of resistance-associated
mutations of HIV-1 to nNRTI is low.1 Compared with efavirenz- or
protease inhibitor(s)-containing regimens, NVP-containing regi-
mens are less likely to cause dyslipidemia.2–4 However, the low
genetic barrier associated with nNRTI-containing regimens in light
of the increasing prevalence of HIV-1 resistant to nNRTIs and the
increasing incidence of skin rashes and hepatotoxicity are the
major concerns with NVP-containing regimens. NVP should beciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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ml and men with CD4 counts >400 cells/ml, and only if beneﬁts
outweigh the risk1; it is contraindicated in patients with moderate
to severe hepatic impairment (Child–Pugh B or C).5
The reported incidence of NVP-associated skin rashes ranges
from 14.5% to 38.3%6–10 and of hepatotoxicity ranges from 15.6% to
46.6%,8,11,12 in different studies, depending on the study popula-
tion, concurrent medications, deﬁnitions used, prevalence of
chronic viral hepatitis, grades of severity studied, and follow-up
durations. Pharmacogenetic studies also suggest that several
alleles of human leukocyte antigens (HLA) in different ethnicities
may be associated with NVP-related hypersensitivity.13–15 In this
study, we aimed to investigate the incidence of NVP-related skin
rashes and hepatotoxicity and factors associated with these in
Taiwan, where the prevalence of chronic hepatitis B virus (HBV)
infection is 18–20% in HIV-infected patients.16
2. Materials and methods
2.1. Study setting and population
As of December 2012, 24 056 cases of HIV infection had been
diagnosed and reported to the Taiwan Centers for Disease Control
(CDC). HIV care, including combination antiretroviral therapy
(cART) and monitoring of CD4 counts and plasma HIV RNA load, is
provided free-of-charge by a special budget of the Taiwan CDC.
According to the national treatment guidelines,17 NVP and
efavirenz remain the recommended nNRTIs when used in
combination with two NRTIs for antiretroviral-naı¨ve HIV-infected
patients in Taiwan, because the prevalence of HIV-1 resistant to
nNRTIs remained low between 2007 and 2010 (2.7%).18 Antiretro-
viral-naı¨ve patients who initiate cART or those who switch to new
regimens are followed 2 and 4 weeks later for the detection of
adverse effects and the assessment of virological and immunolog-
ical responses. The intervals for subsequent follow-ups are at the
discretion of the treating physicians and usually occur 4 to
12 weeks later, depending on the virological response and
detection of adverse effects.
In this retrospective study, we reviewed the medical records of
HIV-infected patients aged 18 years or older who were NVP-naı¨ve
and initiated NVP-containing cART between February 2000 and
October 2012 at the National Taiwan University Hospital and Far
Eastern Memorial Hospital, the two major designated hospitals for
HIV care in northern Taiwan. Patients who were not followed for
4 weeks after starting NVP-containing regimens or who were
pregnant were excluded. A standardized case record form was used
to collect information on demographics, serology of HBV and
hepatitis C virus (HCV), concurrent medications, aminotrans-
ferases, CD4, and plasma HIV RNA load before and during NVP-
containing cART. The study was approved by the research ethics
committees of the two participating hospitals and informed
consent was waived (REC registered number 201003112R).
2.2. Laboratory investigations
The plasma HIV RNA load was quantiﬁed using the Cobas
Amplicor HIV-1 Monitor test (Cobas Amplicor version 1.5; Roche
Diagnostics Corporation, IN, USA) with a lower detection limit of
40 copies/ml. The CD4 count was determined using FACFlow (BD
FACSCalibur; Becton Dickinson, CA, USA). Hepatitis B surface
antigen (HBsAg) was determined with the use of a quantitative,
fully automated chemiluminescent microparticle immunoassay
(ARCHITECT HBsAg; Abbott Diagnostics, Wiesbaden, Germany),
and antibodies to HCV were determined with the use of a
quantitative, fully automated chemiluminescent microparticleimmunoassay (ARCHITECT Anti-HCV; Abbott Diagnostics, Wies-
baden, Germany).
2.3. Deﬁnitions
Hepatotoxicity was deﬁned as follows: grade 0 as an increase in
aminotransferase level to <1.25 times the upper limit of normal
(ULN), grade I as an increase to 1.25–2.5 times ULN, grade II as an
increase to 2.6–5.0 times ULN, grade III as an increase to 5.1–10.0
times ULN, and grade IV as an increase to >10 times ULN, for those
patients with normal aminotransferase levels at baseline.19 For
patients with abnormal aminotransferase levels at baseline,
hepatotoxicity was deﬁned as a two-fold or greater increase from
baseline levels. The severity of NVP-associated skin rashes was
graded according to the National Institutes of Health Division of
AIDS guidelines.19 The decision to discontinue NVP when a skin
rash or hepatotoxicity occurred was made at the discretion of the
treating physicians. An unsatisfactory virological response was
deﬁned as failure to achieve an at least 1 log10 copies/ml decrease
in plasma HIV RNA load from baseline at week 4 of treatment in the
antiretroviral-naı¨ve patients. Treatment failure was deﬁned as
failure to achieve a plasma HIV RNA load of <200 copies/ml in the
antiretroviral-naı¨ve patients after 6 months or longer of treatment,
or the presence of viral rebound in those patient who had ever
achieved viral suppression to <200 copies/ml.
2.4. Statistical analysis
All statistical analyses were performed using SPSS version
17.0 software (SPSS Inc., Chicago, IL, USA). Categorical variables
were compared by Fisher’s exact test or the Chi-square test. Non-
categorical variables were compared by Mann–Whitney U-test.
Factors with a p-value of 0.2 and those that were considered
biologically signiﬁcant were included in the multivariate analysis.
Logistic regression analysis was used to determine the factors
associated with the development of skin rashes and hepatotoxicity.
All comparisons were two-tailed and a p-value <0.05 was
considered signiﬁcant.
3. Results
During the 12-year study period, a total of 338 HIV-infected
patients initiated NVP-containing cART and were followed for
more than 4 weeks; these patients were included in the analysis
(Figure 1).
The clinical characteristics of the patients are shown in
Table 1. The majority of the patients (94.7%) were male, and the
mean CD4 count was 236 cells/ml (46.7% with a CD4 count <200
cells/ml) when NVP-containing cART was initiated. The prevalence
of chronic HBV co-infection was 13.0% and the HCV seroprevalence
was 7.9%. Ten patients (3.0%) were concurrently taking anti-
tuberculosis therapy. More than half of the patients (54.1%) were
antiretroviral-naı¨ve. Ten of the antiretroviral-naı¨ve patients started
NVP-containing regimens when their CD4 counts were >400 cells/
ml, soon after intolerance to other ﬁrst-line regimens developed
before 2011 when raltegravir and rilpivirine were not available. For
the 155 patients (45.9%) who were antiretroviral-experienced, the
switch was made to an NVP-containing regimen because of adverse
effects (gastrointestinal adverse effects, hyperlipidemia, renal colic,
neuropsychiatric adverse effects, and lipodystrophy) (n = 92), a high
pill burden (n = 17), or non-availability of previously used nelﬁnavir,
ritonavir, indinavir, or saquinavir (n = 46).
Of the 338 patients, 286 (84.6%) had baseline aminotransferase
data and 100 (35.0%) had elevated aminotransferase levels,
including 30 patients (10.5%) with a two-fold or greater increase
in aminotransferases and 70 (24.5%) with a less than two-fold
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Figure 1. Study ﬂow of patients receiving nevirapine-containing combination antiretroviral therapy.
Table 1
Clinical characteristics of the patients with and without skin rashes who initiated nevirapine-containing combination antiretroviral therapy
Variables All patients
(N = 338)
Skin rashes
(n = 73)
No skin rashes
(n = 265)
p-Value
Age, years, mean (SD) 37.6 (11.08) 37.3 (11.38) 37.67 (11.02) 0.80
Male gender, n (%) 320 (94.7) 68 (93.2) 252 (95.1) 0.63
Male homosexual, n (%) 320 (94.7) 68 (93.2) 252 (95.1) 0.63
CD4 before NVP, cells/ml, mean (SD) 236 (206) 263 (244) 230 (201) 0.56
ARV-naı¨ve, n (%) 183 (54.1) 38 (52.1) 145 (54.7) 0.75
CD4 of ARV-naı¨ve patientsa, cells/ml, mean (SD) 179 (135) 184 (124) 178 (138) 0.46
CD4 >200, n (%) 83/181 (45.9) 18/38 (47.4) 65/143 (45.5) 0.86
CD4 >350, n (%) 13/181 (7.2) 2/38 (5.3) 11/143 (7.7) 0.74
CD4 >400, n (%) 10/181 (5.5) 2/38 (5.3) 8/143 (5.6) >0.99
ARV-experienced (switch), n (%) 155 (45.9) 35 (47.9) 120 (45.3) 0.08
CD4 at switch to NVPb, cells/ml, mean (SD) 306 (261) 350.9 (310) 393.1 (245) 0.07
CD4 >200, n (%) 94/151 (62.3) 23/34 (67.6) 71/117 (60.7) 0.55
CD4 >350, n (%) 51/151 (33.8) 12/34 (35.3) 39/117 (33.3) 0.84
CD4 >400, n (%) 44/151 (29.1) 10/34 (29.4) 34/117 (29.1) >0.99
Concurrent anti-TB therapy, n (%) 10 (3.0) 1 (1.4) 9 (3.4) 0.47
Concurrent use of TMP/SMX, n (%) 70 (20.7) 15 (20.5) 55 (20.8) >0.99
Baseline aminotransferase level more than two-fold
the upper limit of normal, n (%)
30/286 (10.5) 13/67 (19.4) 17/219 (7.8) 0.01
HBsAg-positive, n (%) 34/262 (13.0) 8/54 (14.8) 26/208 (12.5) 0.82
Anti-HCV-positive, n (%) 22/278 (7.9) 4/57 (7.0) 18/221 (8.1) 0.80
Combined NRTI, n (%)
Abacavir/lamivudine 97 (28.7) 23 (31.5) 74 (27.9) 0.56
Zidovudine/lamivudine 140 (41.4) 27 (37.0) 113 (42.6) 0.42
Other NRTIs 104 (30.8) 24 (32.9) 80 (30.2) 0.67
ARV, antiretroviral agent; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; NRTI, nucleos(t)ide reverse-transcriptase inhibitor; NVP, nevirapine; SD, standard
deviation; TB, tuberculosis; TMP/SMX, trimethoprim/sulfamethoxazole.
a Of 183 antiretroviral-naı¨ve patients, 181 had CD4 count data.
b Of 155 antiretroviral-experienced patients, 151 had CD4 count data.
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ral-naı¨ve. Of the 70 (20.7%) patients receiving trimethoprim/
sulfamethoxazole when NVP was prescribed, 68 (97.1%) had CD4
counts <200 cells/ml.All patients included in this analysis had completed more than
3 months of follow-up and 21.6% (n = 73) developed grade I or
higher skin rashes. There were no statistically signiﬁcant
differences in terms of baseline CD4 count, the proportion of
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proportion of patients with chronic HBV infection or seropositivity
for HCV between those who developed skin rashes and those who
did not. On univariate analysis, we found that patients who
developed skin rashes were signiﬁcantly more likely to have had a
two-fold or greater increase from ULN in aminotransferases before
the initiation of the NVP-containing cART than those who did not
develop skin rashes (19.4% vs. 7.8%, p = 0.01) (Table 1). For those
patients (n = 186) who had normal aminotransferase levels at
baseline, the incidence of NVP-related skin rashes was 16.7%
(n = 31), compared with 36.0% (36/100) for patients with elevated
aminotransferase levels (data not shown).
On multivariate analysis, with adjustments made for gender,
age, baseline CD4 count (treated as either a continuous or
categorical variable), plasma HIV RNA load, being antiretroviral-
naı¨ve, and combination therapy with abacavir or trimethoprim/
sulfamethoxazole (Table 2), we found that a two-fold or greater
than ULN of aminotransferases at baseline was signiﬁcantly
associated with NVP-related skin rashes, with an adjusted odds
ratio (aOR) of 3.74 (95% conﬁdence interval (CI) 1.56–8.96,
p < 0.01). The median interval from initiation of NVP to the
development of skin rashes was 14 days (interquartile range (IQR)
10–26 days), with the longest interval being 84 days (Figure 2).
Subgroup analyses among antiretroviral-naı¨ve and antiretrovi-
ral-experienced patients revealed different results (Supplemen-
tary Material, Tables S1–S3). A two-fold or greater increase in
aminotransferase from ULN at baseline was associated with NVP-
related skin rashes among antiretroviral-naı¨ve patients (aOR 5.30,
95% CI 1.48–18.97, p = 0.01). For antiretroviral-experiencedTable 2
Multivariate analysis of factors associated with nevirapine-related skin rashesa
aOR 95% CI p-Value
Age, per 1-year increase 0.99 0.96–1.03 0.72
Sex, male vs. female 0.81 0.16–4.00 0.79
CD4, per 50 cells/ml increase 1.06 0.98–1.13 0.11
Baseline aminotransferase two-fold or
greater than the upper limit of normal
3.74 1.56–8.96 <0.01
aOR, adjusted odds ratio; CI, conﬁdence interval; HBsAg, hepatitis B surface antigen;
HCV, hepatitis C virus.
a Adjustments for sex, age, baseline CD4, and plasma HIV RNA load before
initiation of nevirapine-containing antiretroviral therapy, being antiretroviral-
naı¨ve, and concurrent use of abacavir or trimethoprim/sulfamethoxazole, HBsAg
positivity, and anti-HCV positivity.
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Figure 2. Timing of the onset of skin rashes in the 73 patients who developed this
adverse effect after initiation of nevirapine-containing combination antiretroviral
therapy. The x-axis denotes the days after initiation of nevirapine, while the y-axis
denotes the percentage of patients who developed nevirapine-related skin rashes.patients, higher plasma HIV RNA loads were associated with
NVP-related skin rashes (aOR 1.56, 95% CI 1.03–2.35, p = 0.03), but
a two-fold or greater increase in aminotransferase than ULN
at baseline was of borderline statistical signiﬁcance (aOR 3.93,
95% CI 0.99–15.55, p = 0.05). Eleven patients (15.1%) with skin
rashes, including one with generalized maculopapular rashes and
two also with hepatotoxicity, continued NVP-containing cART
under close monitoring and the skin rashes resolved. For seven
patients (9.6%) who also developed hepatotoxicity and fever,
with or without mucosal swelling, the rashes resolved with
discontinuation of NVP.
Among the 106 patients with both baseline and follow-up
aminotransferase data, 27 (25.5%) developed hepatotoxicity.
Patients with hepatotoxicity had higher baseline CD4 counts than
those without hepatotoxicity after the initiation of NVP-containing
regimens (Table 3). Thirteen out of 75 patients (17.3%) who had
normal liver function at baseline developed hepatotoxicity after
initiation of the NVP-containing regimen, including one grade II,
seven grade III, and ﬁve grade IV. On multivariate analysis, CD4
count (aOR for per 50 cells/ml increase 1.51, 95% CI 1.12–2.03,
p = 0.01) and concurrent trimethoprim/sulfamethoxazole use (aOR
14.01, 95% CI 1.98–98.95, p = 0.01) were signiﬁcantly associated
with NVP-related hepatotoxicity (Table 4), while HCV seropositiv-
ity showed a borderline association (aOR 7.39, 95% CI 0.74–74.22,
p = 0.09) (data not shown). The median interval between initiation
of NVP-containing cART and hepatotoxicity was 28.5 days (IQR
26.3–33.5 days). In the patients with baseline and follow-up
aminotransferase data, six of 10 male patients (60.0%) who had
baseline CD4 400 cells/ml, developed grade II or higher
hepatotoxicity, as compared to 20 of 91 patients (22.0%) who
had baseline CD4 <400 cells/ml (aOR 10.00, 95% CI 2.06–48.56,
p < 0.01) (Table 4).
Within the ﬁrst 4 weeks of NVP-containing cART, 18.0% of the
patients (n = 61) had to change the regimen. This was because of an
unsatisfactory virological response in the antiretroviral-naı¨ve
patients who failed to achieve an at least 1 log10 copies/ml
decrease in plasma HIV RNA load from baseline at week 4 of
treatment (n = 2, 3.3%), or to adverse effects due to rashes (n = 45,
73.8%) or hepatotoxicity (n = 5, 8.2%; including three who also had
skin rashes); the reason was not clearly described in the medical
records for the remaining 12 patients (19.7%).
During follow-up, 48.5% (n = 164) of patients changed regi-
mens, including 62 (37.8%) because of skin rashes (median interval
between initiation and discontinuation, 14 days), 16 (9.8%)
because of hepatotoxicity (median interval, 28 days), 38 (23.2%)
because of treatment failure (median interval, 112 days), and 50
(30.5%) for other miscellaneous reasons (median interval, 140 days)
(Figure 1). There were no cases of Stevens–Johnson syndrome, liver
failure, or mortality related to NVP-containing regimens.
4. Discussion
In this study conducted among HIV-infected ethnic Chinese
patients in the cART era, we found the overall incidence of skin
rashes to be 21.6% and of hepatotoxicity to be 25.5%. Elevated
aminotransferase levels at baseline was associated with NVP-
related skin rashes, while higher CD4 counts and the concurrent
use of trimethoprim/sulfamethoxazole were associated with
hepatotoxicity. The borderline association between HCV seroposi-
tivity and hepatotoxicity is likely due to the small number of cases
who were seropositive for HCV enrolled in the study.
The incidences of NVP-related skin rashes (21.6%) and
hepatotoxicity (25.5%) in this study are higher than those reported
in a prospective study in Thailand (16.1% and 15.6%, respectively)8
that included male (19.1%), non-pregnant female (21.3%), and
pregnant female (59.7%) patients with baseline CD4 counts of 136,
Table 3
Clinical characteristics of patients with or without hepatotoxicity after the initiation of nevirapine-containing antiretroviral therapy who had aminotransferase data at
baseline and during follow-up
All patients
(N = 106)
With hepatotoxicity
(n = 27)
Without hepatotoxicity
(n = 79)
p-Value
Age, years, mean (SD) 36.6 (10.96) 36.1 (7.13) 36.8 (12.09) 0.8
Male gender, n (%) 101 (95.3) 26 (96.3) 75 (94.9) >0.99
Male homosexual, n (%) 101 (95.3) 26 (96.3) 75 (94.9) >0.99
CD4 before NVP, cells/ml, mean (SD) 209 (223) 330 (356) 169 (134) <0.01
ARV-naı¨ve, n (%) 84 (79.2) 20 (74.1) 64 (81.0) 0.58
CD4 of ARV-naı¨ve patients, cells/ml, mean (SD) 178 (132) 228 (157) 163 (120) 0.12
CD4 >200, n (%) 36/84 (42.9) 12/20 (60) 24/64 (37.5) 0.12
CD4 >350, n (%) 6/84 (7.1) 3/20 (15) 3/64 (4.7) 0.14
CD4 >400, n (%) 5/84 (6.0) 3/20 (15) 2/64 (3.1) 0.09
ARV-experienced (switch), n (%) 22 (20.8) 7 (25.9) 15 (19.0) 0.58
CD4 at switch to NVP, cells/ml, mean (SD) 329 (402) 620 (581) 193 (186) <0.01
CD4 >200, n (%) 12/22 (54.5) 5/7 (71.4) 7/15 (46.7) 0.38
CD4 >350, n (%) 6/22 (27.3) 4/7 (57.1) 2/15 (13.3) 0.05
CD4 >400, n (%) 6/22 (27.3) 4/7 (57.1) 2/15 (13.3) 0.05
Concurrent anti-TB therapy, n (%) 1 (0.9) 0 (0) 1 (1.3) >0.99
Concurrent use of TMP/SMX, n (%) 26 (24.5) 7 (25.9) 19 (24.1) >0.99
Baseline aminotransferase level more than
two-fold the upper limit of normal, n (%)
7 (6.6) 1 (3.7) 6 (7.6) 0.68
HBsAg-positive, n (%) 14/95 (14.7) 5/26 (19.2) 9/69 (13.0) 0.52
Anti-HCV-positive, n (%) 6/102 (5.9) 3 (11.1) 3/75 (4.0) 0.34
Combined NRTI, n (%)
Abacavir/lamivudine 36 (34.0) 8 (29.6) 28 (35.4) 0.64
Zidovudine/lamivudine 28 (26.4) 5 (18.5) 23 (29.1) 0.32
Other NRTIs 43 (40.6) 14 (51.9) 29 (36.7) 0.18
Development of skin rashes, n (%) 16 (15.1) 7 (25.9) 9 (11.4) 0.12
ARV, antiretroviral agent; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; NRTI, nucleos(t)ide reverse-transcriptase inhibitor; NVP, nevirapine; SD, standard
deviation; TB, tuberculosis; TMP/SMX, trimethoprim/sulfamethoxazole.
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female Thai patients (8.0%), male patients had a higher rate (24.4%)
of developing NVP-related hepatotoxicity of grade I or higher, but
the baseline CD4 cell count was not associated with hepatotoxicity
or skin rashes. Although our study population comprised mainly
male patients (94.7%) and more of our patients had abnormal
baseline aminotransferase levels (35.0%), the incidence of NVP-
related hepatotoxicity was similar between our study and the Thai
study in which only 4.9% of the male patients had abnormal
aminotransferase levels at baseline.8Table 4
Factors associated with hepatotoxicity after initiation of nevirapine-containing
antiretroviral therapy on multivariate analysisa
aOR 95% CI p-Value
Model Ib
CD4, per 50 cells/ml increase 1.51 1.12–2.03 0.01
Use of TMP/SMX 14.01 1.98–98.95 0.01
Model IIb
Baseline CD4 >200 cells/ml 5.73 1.15–28.53 0.03
Use of TMP/SMX 5.45 0.96–31.05 0.06
Model IIIb
CD4, per 50 cells/ml increase 1.41 1.05–1.90 0.02
Use of TMP/SMX 11.22 1.66–76.01 0.01
Model IVb
Baseline CD4 >400 cells/ml 10.00 2.06–48.56 <0.01
Use of TMP/SMX 2.92 0.88–9.70 0.08
aOR, adjusted odds ratio; CI, conﬁdence interval; TMP/SMX, trimethoprim/
sulfamethoxazole; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus.
a Adjustments for sex, age, baseline CD4, and plasma HIV RNA load before
initiation of nevirapine-containing antiretroviral therapy, being antiretroviral-
naı¨ve, and concurrent use of abacavir or TMP/SMX, HBsAg positivity, and anti-HCV
positivity.
b The difference between model I and model II, and between model III and model
IV is that CD4 count is treated as either a continuous variable or a categorical
variable in the multivariate analysis. The difference between model I and model III
is that both male and female patients are included in model I, while only male
patients are included in model III.Carriage of several HLA alleles has been reported to be
associated with the development of NVP-associated hypersensi-
tivity.13–15 However, these genetic tests remain investigational
and the results may differ among ethnicities and may not be easily
accessible to clinicians in resource-limited settings. In this study,
we identiﬁed abnormal liver function at baseline as a statistically
signiﬁcant factor associated with NVP-related skin rashes (aOR
3.74), especially in antiretroviral-naı¨ve ethnic Chinese patients.
This clinical variable is easily available to clinicians and can be used
to help reduce the risk of skin rashes in those patients for whom
NVP-containing cART is considered. For example, the incidence of
NVP-related skin rashes could potentially have been reduced from
36.0% to 16.7% in our study if the use of NVP had been strictly
limited to those patients with normal aminotransferase levels at
baseline.
The risk of NVP-associated hepatotoxicity has been shown to
be signiﬁcantly higher in female patients with CD4 >250 cells/ml
and in male patients with CD4 >400 cells/ml at the time of
NVP initiation20,21 and therefore it is advised that NVP be used
with caution in these patients.5 In a retrospective study
conducted by Gao and colleagues in ethnic Chinese patients in
2010,11 the incidence of hepatotoxicity was 46.4% for grade I or
higher and 22.7% for grade II or higher hepatotoxicity in HIV-
infected patients for whom 80.9% of the cART consisted of NVP. On
multivariate analysis, exposure to NVP, elevated aminotrans-
ferases at baseline, and HCV infection were associated with
hepatotoxicity. However, few patients in the study by Gao et al.
had a baseline CD4 count of 200 cells/ml, which may limit the
study from identifying the association between hepatotoxicity
and higher CD4 counts. In this study also conducted in ethnic
Chinese, we found higher CD4 counts (>200 cells/ml) and the
concurrent use of trimethoprim/sulfamethoxazole to be associ-
ated with NVP-related hepatotoxicity (Table 4). The ﬁndings of
our study suggest that caution is warranted in the use of NVP in
male Chinese patients who have higher baseline CD4 counts
(>200 cells/ml).
Y.-T. Tseng et al. / International Journal of Infectious Diseases 29 (2014) 12–17 17There are several limitations to this study. First, this was a
retrospective study and we were not able to collect clinical
information on the daily amount of alcohol consumed or
adherence to the prescribed regimens. Furthermore, only
106 out of 338 patients had baseline and follow-up aminotrans-
ferase data available, and incomplete data for baseline as well as
follow-up aminotransferases might have confounded our
results. Nevertheless our ﬁnding of a strong association between
CD4 >400 cells/ml at baseline and an increased risk of
hepatotoxicity also supports caution in the use of NVP in the
guidelines.1,5 Second, the number of cases with chronic HCV
infection was small in our study population, which may preclude
us from identifying chronic HCV infection as a statistically
signiﬁcant factor associated with hepatotoxicity. Third, we
included all grades of severity of rash and hepatotoxicity in
the analysis. The noted incidence of hepatotoxicity would be
lower if a higher grade of severity, such as ﬁve-fold or greater,
was used. Fourth, the overall loss-to-follow-up rate in these two
hospitals was about 8% (Figure 1), which may preclude us from
precisely estimating the incidence of skin rashes and hepato-
toxicity. Fifth, the results may not be generalizable to other HIV-
infected populations such as injecting drug users or females,
because the majority of the patients included were men who
have sex with men. Sixth, 20% of the patients were taking
trimethoprim/sulfamethoxazole, an antimicrobial agent with a
high incidence of skin rashes and hepatotoxicity (15–20%)
among HIV-infected patients.22,23 Because of the retrospective
study design, it was difﬁcult to differentiate between NVP and
trimethoprim/sulfamethoxazole when skin rashes occurred.
However, in the multivariate analysis, the use of trimetho-
prim/sulfamethoxazole was not shown to be associated with
skin rashes. Similarly, abacavir, which was used in 28% of our
patients, was not associated with skin rashes either, probably
because of a low carriage rate (0.3%) of HLA B*5701 in Taiwanese
patients.24
In conclusion, the incidences of NVP-related skin rash and
hepatotoxicity were 21.6% and 25.5%, respectively. Abnormal liver
function at baseline was associated with skin rashes, while a
baseline CD4 count >200 cells/ml and the concurrent use of
trimethoprim/sulfamethoxazole were associated with hepatotox-
icity after the initiation of NVP-containing cART in HIV-infected
Taiwanese patients.
Acknowledgements
The authors would like to thank the Taiwan Centers for
Disease Control for research grant support and Dr Aristine Cheng,
National Taiwan University Hospital Hsin-Chu Branch, Taiwan,
for the English language editing and critical review of the
manuscript.
Funding source: The study was sponsored by the Taiwan Centers
for Disease Control (grant number DOH102-DC-1401 to C.-C. H.).
The funding source had no role in the study design, conduct, data
collection and analysis, preparation of the manuscript, or decision
to submit.
Conﬂict of interest: All authors have no conﬂicts of interest to
declare.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ijid.2014.08.012.References
1. European AIDS Clinical Society. European guidelines for treatment of
HIV-infected adults in Europe. EACS; 2012.
2. Podzamczer D, Andrade-Villanueva J, Clotet B, Taylor S, Rockstroh JK, Reiss P,
et al. Lipid proﬁles for nevirapine vs. atazanavir/ritonavir, both combined with
tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-
naive HIV-1-infected patients (the ARTEN study). HIV Med 2011;12:374–82.
3. Arpadi S, Shiau S, Strehlau R, Martens L, Patel F, Coovadia A, et al. Metabolic
abnormalities and body composition of HIV-infected children on lopinavir or
nevirapine-based antiretroviral therapy. Arch Dis Child 2013;98:258–64.
4. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Rafﬁ F, et al. Nevirapine
and efavirenz elicit different changes in lipid proﬁles in antiretroviral-therapy-
naive patients infected with HIV-1. PLoS Med 2004;1:e19.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for
the use of antiretroviral agents in HIV-1-infected adults and adolescents.
Department of Health and Human Services, 2014. Available at http://aidsinfo.
nih.gov/contentﬁles/lvguidelines/AdultandAdolescentGL.pdf (accessed October
18, 2014).
6. Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, et al.
Incidence and risk factors for rash in Thai patients randomized to regimens with
nevirapine, efavirenz or both drugs. AIDS 2005;19:185–92.
7. Antinori A, Baldini F, Girardi E, Cingolani A, Zaccarelli M, Di Giambenedetto S, et al.
Female sex and the use of anti-allergic agents increase the risk of
developing cutaneous rash associated with nevirapine therapy. AIDS 2001;15:
1579–81.
8. Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithongwongwatthana S,
Taweepolcharoen C, Mangclaviraj S, et al. Nevirapine-associated toxicity in
HIV-infected Thai men and women, including pregnant women. HIV Med
2007;8:357–66.
9. de Maat MM, ter Heine R, Mulder JW, Meenhorst PL, Mairuhu AT, van Gorp EC,
et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin
Pharmacol 2003;59:457–62.
10. Pollard RB, Robinson P, Dransﬁeld K. Safety proﬁle of nevirapine, a nonnucleo-
side reverse transcriptase inhibitor for the treatment of human immunodeﬁ-
ciency virus infection. Clin Ther 1998;20:1071–92.
11. Gao S, Gui XE, Deng L, Zhang Y, Liang K, Yang R, et al. Antiretroviral therapy
hepatotoxicity: prevalence, risk factors, and clinical characteristics in a cohort
of Han Chinese. Hepatol Res 2010;40:287–94.
12. Jena A, Sachdeva RK, Sharma A, Wanchu A. Adverse drug reactions to non-
nucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week
prospective study. J Int Assoc Physicians AIDS Care (Chic) 2009;8:318–22.
13. Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungka-
nuparph S, Manosuthi W, et al. HLA-B*3505 allele is a strong predictor for
nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.
Pharmacogenet Genomics 2009;19:139–46.
14. Likanonsakul S, Rattanatham T, Feangvad S, Uttayamakul S, Prasithsirikul W,
Tunthanathip P, et al. HLA-Cw*04 allele associated with nevirapine-induced
rash in HIV-infected Thai patients. AIDS Res Ther 2009;6:22.
15. Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from
analysis of HLA alleles. Pharmacogenomics 2008;9:207–14.
16. Sun HY, Ko WC, Tsai JJ, Lee HC, Liu CE, Wong WW, et al. Seroprevalence of
chronic hepatitis B virus infection among Taiwanese human immunodeﬁciency
virus type 1-positive persons in the era of nationwide hepatitis B vaccination.
Am J Gastroenterol 2009;104:877–84.
17. Center for Disease Control. Guidelines for diagnosis and treatment of HIV/AIDS.
Taiwan: CDC; 2010. Available at: http://www.cdc.gov.tw/infectionreportinfo.
aspx?treeid=075874dc882a5bfd&nowtreeid=8dba723ff186fac0&tid=
3B00A7FD7543115A (accessed August 4, 2014).
18. Lai CC, Hung CC, Chen MY, Sun HY, Lu CL, Tseng YT, et al. Trends of transmitted
drug resistance of HIV-1 and its impact on treatment response to ﬁrst-line
antiretroviral therapy in Taiwan. J Antimicrob Chemother 2012;67:1254–60.
19. National Institutes of Health. Division of AIDS table for grading the severity of
adult and pediatric adverse events, 2004 (Clariﬁcation August 2009)., 2009.
Available at: http://rsc.tech-res.com/document/safetyandpharmacovigilance/
table_for_grading_severity_of_adult_pediatric_adverse_events.pdf (accessed
April 8, 2013).
20. Boehringer Ingelheim Pharmaceuticals, Inc. Dear Health Care Professional
Letter: Clariﬁcation of risk factors for severe, life-threatening and fatal hepa-
totoxicity with VIRAMUNE1 (nevirapine)., 2004. Available at: http://
www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlerts-
forHumanMedicalProducts/UCM166534.pdf (accessed April 17, 2013).
21. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use.
JAcquir Immune Deﬁc Syndr 2004;35:538–9.
22. Hennessy S, Strom BL, Berlin JA, Brennan PJ. Predicting cutaneous hypersensi-
tivity reactions to cotrimoxazole in HIV-infected individuals receiving primary
Pneumocystis carinii pneumonia prophylaxis. J Gen Intern Med 1995;10:380–6.
23. Yang JJ, Huang CH, Liu CE, Tang HJ, Yang CJ, Lee YC, et al. Multicenter study of
trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associ-
ated factors among HIV-infected patients treated for Pneumocystis jirovecii
pneumonia. PLoS One 2014;9:e106141.
24. Sun HY, Hung CC, Lin PH, Chang SF, Yang CY, Chang SY, et al. Incidence of
abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected
patients in Taiwan. J Antimicrob Chemother 2007;60:599–604.
